中国神经再生研究(英文版) ›› 2019, Vol. 14 ›› Issue (11): 1893-1894.doi: 10.4103/1673-5374.259609

• 观点:神经损伤修复保护与再生 • 上一篇    下一篇

Sigma-2受体作为治疗中枢神经系统疾病的潜在治疗靶点

  

  • 出版日期:2019-11-15 发布日期:2019-11-15

Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders

Kazuki Terada 1, Keisuke Migita 2, Yukari Matsushima 3, Chiaki Kamei 3   

  1. 1Laboratory of Drug Design and Drug Delivery, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan;
    2Department of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan;
    3Department of Pharmacology, Faculty of Pharmaceutical Sciences, Yasuda Women’s University, Hiroshima, Japan
  • Online:2019-11-15 Published:2019-11-15
  • Contact: Kazuki Terada, PhD, kterada@fukuoka-u.ac.jp.
  • Supported by:

    This work was supported by Japan Society for the Promotion of Science KAKENHI (JP16K18888, to KT).

摘要:

orcid: 0000-0003-0257-5812 (Kazuki Terada)

Abstract:

The sigma receptor (Sig-R) was first reported by Martin et al. and was initially classified into the opioid receptor family. However, Sig-R was subsequently found to differ from the opioid receptor in various studies including ligand binding assays and autoradiography analysis. Sig-R is widely distributed in tissues such as central nervous, digestive, immune, and endocrine tissues. There are two types of Sig-R: sigma-1 (Sig-1R) and sigma-2 receptors (Sig-2R). Recent studies reported that each subtype has distinct cellular and physiological functions. Since Hanner et al. successfully cloned the Sig-1R gene, the functions of Sig-1R have been widely evaluated in the fields of cell biology, molecular biology, cancer, immunology, and behavioral neuroscience. Particularly, it has been suggested that Sig-1R activates neurons in the central nervous system (CNS) and contributes to physiological functions such as memory and cranial nerve protection. In contrast, Sig-2R has not been cloned. Sig-2R is thought to be involved in cellular processes related to neuropathy, as pharmacological studies suggested that Sig-2R is widely distributed in the CNS. Recently, Alon et al. identified the gene encoding Sig-2R. This perspective focuses on whether Sig-2R is useful as a therapeutic target for CNS disorders such as Alzheimer’s disease, Parkinson’s disease, and depression, based on the structure of Sig-2R and its role in nerve growth.